Fig. 2

S100β associates with poor disease-free survival times in patients with endocrine-treated breast cancer. a S100β tissue expression strongly associated with poor disease-free survival in a TMA patient cohort of 509 ERα-positive, endocrine-treated patients as determined by Kaplan-Meier estimates of disease-free survival (HR 2.32, 95% CI is 1.58–3.40, p < 0.0001, Cox proportional hazard model). b 187 endocrine-treated ERα-positive patient serum samples were analyzed by ELISA for S100β using the established cut-off of 0.13 μg/L. S100β serum levels significantly associated with poor disease-free survival in the endocrine therapy-treated patient population (HR 3.09, 95% CI is 1.66–9.68, p = 0.002, Cox proportional hazard model). c Pre-operative elevated serum S100β returned to normal following surgical resection of the tumor in matched patient blood samples as measured by ELISA (55 individual patients, 6 pre-operative S100β ≥0.13 and 49 pre-operative S100β <0.13, paired t test error bars refer to 95% CI, p = 0.023)